These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 30890654)

  • 1. Potential therapeutic targets for atherosclerosis in sphingolipid metabolism.
    Yu Z; Peng Q; Huang Y
    Clin Sci (Lond); 2019 Mar; 133(6):763-776. PubMed ID: 30890654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sphingolipid metabolism and atherosclerosis.
    Jiang XC; Liu J
    Handb Exp Pharmacol; 2013; (216):133-46. PubMed ID: 23563655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sphingolipids in Atherosclerosis: Chimeras in Structure and Function.
    Peters L; Kuebler WM; Simmons S
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene expression of sphingolipid metabolism pathways is altered in hidradenitis suppurativa.
    Dany M; Elston D
    J Am Acad Dermatol; 2017 Aug; 77(2):268-273.e6. PubMed ID: 28551069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sphingolipids in psychiatric disorders and pain syndromes.
    Mühle C; Reichel M; Gulbins E; Kornhuber J
    Handb Exp Pharmacol; 2013; (216):431-56. PubMed ID: 23563670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An overview of sphingolipid metabolism: from synthesis to breakdown.
    Gault CR; Obeid LM; Hannun YA
    Adv Exp Med Biol; 2010; 688():1-23. PubMed ID: 20919643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sphingolipid metabolizing enzymes as novel therapeutic targets.
    Billich A; Baumruker T
    Subcell Biochem; 2008; 49():487-522. PubMed ID: 18751924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of inhibitors of key enzymes of sphingolipid metabolism on insulin-induced glucose uptake and glycogen synthesis in liver cells of old rats.
    Babenko NA; Kharchenko VS
    Biochemistry (Mosc); 2015 Jan; 80(1):104-12. PubMed ID: 25754045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rewiring Endothelial Sphingolipid Metabolism to Favor S1P Over Ceramide Protects From Coronary Atherosclerosis.
    Manzo OL; Nour J; Sasset L; Marino A; Rubinelli L; Palikhe S; Smimmo M; Hu Y; Bucci MR; Borczuk A; Elemento O; Freed JK; Norata GD; Di Lorenzo A
    Circ Res; 2024 Apr; 134(8):990-1005. PubMed ID: 38456287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel agents targeting bioactive sphingolipids for the treatment of cancer.
    Adan-Gokbulut A; Kartal-Yandim M; Iskender G; Baran Y
    Curr Med Chem; 2013; 20(1):108-22. PubMed ID: 23244584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Druggable Sphingolipid Pathways: Experimental Models and Clinical Opportunities.
    Blaho VA
    Adv Exp Med Biol; 2020; 1274():101-135. PubMed ID: 32894509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases.
    Canals D; Perry DM; Jenkins RW; Hannun YA
    Br J Pharmacol; 2011 Jun; 163(4):694-712. PubMed ID: 21615386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet extracellular vesicles mediate transfusion-related acute lung injury by imbalancing the sphingolipid rheostat.
    McVey MJ; Weidenfeld S; Maishan M; Spring C; Kim M; Tabuchi A; Srbely V; Takabe-French A; Simmons S; Arenz C; Semple JW; Kuebler WM
    Blood; 2021 Feb; 137(5):690-701. PubMed ID: 33232973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitors of the sphingomyelin cycle: Sphingomyelin synthases and sphingomyelinases.
    Adada M; Luberto C; Canals D
    Chem Phys Lipids; 2016 May; 197():45-59. PubMed ID: 26200918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sphingolipid synthetic pathways are major regulators of lipid homeostasis.
    Worgall TS
    Adv Exp Med Biol; 2011; 721():139-48. PubMed ID: 21910087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging Roles of Ceramides in Breast Cancer Biology and Therapy.
    Pal P; Atilla-Gokcumen GE; Frasor J
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sphingolipids in neurodegeneration (with focus on ceramide and S1P).
    Wang G; Bieberich E
    Adv Biol Regul; 2018 Dec; 70():51-64. PubMed ID: 30287225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiology and pathophysiology of sphingolipid metabolism and signaling.
    Huwiler A; Kolter T; Pfeilschifter J; Sandhoff K
    Biochim Biophys Acta; 2000 May; 1485(2-3):63-99. PubMed ID: 10832090
    [No Abstract]   [Full Text] [Related]  

  • 19. Differential regulation of sphingolipid metabolism in plasma, hippocampus, and cerebral cortex of mice administered sphingolipid modulating agents.
    Giles C; Takechi R; Mellett NA; Meikle PJ; Dhaliwal S; Mamo JC
    J Neurochem; 2017 May; 141(3):413-422. PubMed ID: 28129448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sphingolipids in the lungs.
    Uhlig S; Gulbins E
    Am J Respir Crit Care Med; 2008 Dec; 178(11):1100-14. PubMed ID: 18755926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.